RedHill Biopharma to Present at the 25th Annual ROTH Conference
TEL-AVIV, Israel, March 6, 2013 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd.
(Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"), an emerging Israeli
biopharmaceutical company focused primarily on the development and acquisition
of late clinical-stage, patent-protected, new formulations and combinations of
existing drugs, today announced that Dror Ben-Asher, the Company's Chief
Executive Officer, will present an overview of the Company at the 25^th Annual
ROTH Conference. The RedHill presentation will take place at the Ritz Carlton
in Laguna Niguel, on Tuesday, March 19, 2013 at 10:30am PDT.
About RedHill Biopharma Ltd.:
RedHill Biopharma is an emerging Israeli biopharmaceutical company focused
primarily on the development and acquisition of late clinical-stage, patent
protected, new formulations and combinations of existing drugs. The Company's
current product pipeline includes a once-daily formulation of a leading
congestive heart failure and high blood pressure drug, a once-daily
formulation of a leading chemotherapy and radiotherapy-induced nausea and
vomiting prevention drug, an oral thin film formulation drug for the treatment
of acute migraine, a combination therapy for the treatment of Crohn's disease
as well as Multiple Sclerosis (MS), a combination therapy for the treatment of
Helicobacter pylori bacteria causing ulcers, and an encapsulated formulation
for bowel preparation (laxative) ahead of colonoscopy. For more information
please visit: www.redhillbio.com.
CONTACT: PR contact (US):
The Trout Group
Senior VP Business Development & Licensing
Press spacebar to pause and continue. Press esc to stop.